This site is intended for health professionals only
Wednesday 22 May 2019
Share |

Industry News

Six in 10 pharmacy professionals in favour of banning homeopathy prescribing

Friday 7th September 2018

Six in 10 pharmacy professionals are against the sale and dispensing of homeopathic products, pharmacists at an international conference have heard.
 
In a congress session taking place at the International Pharmaceutical Federation’s (FIP) World Congress of Pharmacy and Pharmaceutical Science on Tuesday (4 September), 63% of between 150 to 200 people surveyed said ‘...

Fri, 26 Jun 2015
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the expanded use of Levemir® (insulin detemir) in children with diabetes as young as one year old
Fri, 26 Jun 2015
Adults with non-radiographic axial spondyloarthritis can be considered for once-monthly subcutaneous injection with SIMPONI® (golimumab)
Wed, 24 Jun 2015
Data presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting 2015 by Bristol-Myers Squibb (BMS) suggests that its Opdivo/Yervoy combination of immunotherapies to treat metastatic melanoma will shape the therapeutic landscape once it is approved, says an analyst with research and consulting firm GlobalData.
Tue, 16 Jun 2015
New analyses from the EINSTEIN Clinical Trial Programme provide further data regarding the positive benefit–risk profile of Xarelto in specific patient populations. (1) Observational data from independent study in the UK provide real life insights into the risk of VTE in patients with active cancer. (1)
Wed, 10 Jun 2015
More than 200,000 people in the UK are chronically infected with hepatitis C, (1) of which only an estimated 3% are treated each year, despite the advent of treatments that can offer viral elimination. (1)
Wed, 10 Jun 2015
Merck Sharp & Dohme (MSD), known as Merck in the United States and Canada, announced additional data from a subanalysis (1) of the multicentre, randomised, double-blind, placebo-controlled GO-AHEAD study on the effect of SIMPONI® (golimumab) in treating patients with non-radiographic axial spondyloarthritis (nr-axial SpA). (2)
Wed, 10 Jun 2015
The comparable safety and efficacy of switching patients to a biosimilar anti-TNF-alpha monoclonal antibody from the reference medicinal product (RMP) has been further established in data presented at EULAR 2015, the annual meeting of the European League Against Rheumatism. Data from abstracts published or presented at the conference show that the effectiveness of biosimilar infliximab CT-P13, developed and manufactured by Celltrion, Inc., was similar to the RMP in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients who were switched from the RMP to the biosimilar infliximab, with no additional safety signals. (1)

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine